| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/27/2011 | CA2440042C Carboxamide derivatives as therapeutic agents |
| 09/27/2011 | CA2418109C Polymorphs of an epothilone analog |
| 09/27/2011 | CA2415847C Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 09/27/2011 | CA2412600C Potent immunostimulatory polysaccharides extracted from microalgae |
| 09/27/2011 | CA2408034C Recombinant sequence, its preparation and use |
| 09/27/2011 | CA2403790C A cell division inhibitor and a production method thereof |
| 09/27/2011 | CA2370206C Pharmaceutical compositions for inhibition of cytokine production and secretion |
| 09/27/2011 | CA2258728C Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| 09/22/2011 | WO2011116344A2 Targeting cancer stem cells |
| 09/22/2011 | WO2011116336A1 Nitroxyl (hno) releasing compounds and uses thereof in treating diseases |
| 09/22/2011 | WO2011116226A2 Display of antibody fragments on virus-like particles of rna bacteriophages |
| 09/22/2011 | WO2011116014A2 Humanized antibodies to labyrinthin and uses thereof |
| 09/22/2011 | WO2011115998A2 Modulators of hec1 activity and methods therefor |
| 09/22/2011 | WO2011115810A2 Isoform-specific rnai based on codon redundancy/degeneracy |
| 09/22/2011 | WO2011115725A2 Indazole compounds and their uses |
| 09/22/2011 | WO2011115688A2 Integrin interaction inhibitors for the treatment of cancer |
| 09/22/2011 | WO2011115651A2 Natural plant products for control of cancer metastasis |
| 09/22/2011 | WO2011115513A2 A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation |
| 09/22/2011 | WO2011115271A1 Tumor angiogenesis inhibitor |
| 09/22/2011 | WO2011115268A1 Tumor angiogenesis inhibitor |
| 09/22/2011 | WO2011115183A1 Novel monocyclic pyrimidine derivative |
| 09/22/2011 | WO2011115062A1 Adjuvant having anti-tumor effect |
| 09/22/2011 | WO2011114275A1 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 09/22/2011 | WO2011114246A1 Process for the preparation of malic acid salt of sunitinib |
| 09/22/2011 | WO2011114137A1 Toluidine blue derivatives as photosensitising compounds |
| 09/22/2011 | WO2011114071A2 Synthetic cyclopeptide, preparation process and uses |
| 09/22/2011 | WO2011113981A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 09/22/2011 | WO2011113892A2 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 09/22/2011 | WO2011113882A1 Diagnosis and treatment of cancer based on avl9 |
| 09/22/2011 | WO2011113872A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 09/22/2011 | WO2011113862A1 Imidazopyrazines |
| 09/22/2011 | WO2011113616A1 A nanoparticle comprising a micelle formed by an amphiphilic block- copolymer and encapsulating a gadolinium complex |
| 09/22/2011 | WO2011113604A1 Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein |
| 09/22/2011 | WO2011113600A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/22/2011 | WO2011113578A1 New oxadiazole derivatives |
| 09/22/2011 | WO2011113512A1 Morpholinylquinazolines |
| 09/22/2011 | WO2011113370A1 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising these compounds |
| 09/22/2011 | WO2011113368A1 Preparation method of fluoro-substituted deuterated diphenylurea |
| 09/22/2011 | WO2011113367A1 Method and process for preparation and production of deuterated ω-diphenylurea |
| 09/22/2011 | WO2011113366A1 Method for preparing deuterated diphenylurea |
| 09/22/2011 | WO2011113308A1 New humanized anti-cd20 monoclonal antibody |
| 09/22/2011 | WO2011113301A1 Self-emulsifying formulation of taxanes and preparation method thereof |
| 09/22/2011 | WO2011113300A1 Medicines for inhibiting toxicity or side effects caused by chemotherapeutic agents |
| 09/22/2011 | WO2011113293A1 Dihydropteridinone derivatives, preparation method and pharmaceutical use thereof |
| 09/22/2011 | WO2011113284A1 Shikonin naphthazarin derivatives, preparation method and antitumor use thereof |
| 09/22/2011 | WO2011113203A1 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 09/22/2011 | WO2011113175A1 Cytarabine prodrug derivatives and use for resisting cancer or tumor thereof |
| 09/22/2011 | WO2011113174A1 Cytarabine derivatives and uses for anticancer and antitumor thereof |
| 09/22/2011 | WO2011113173A1 Cytarabine prodrug derivatives and use for resisting cancer or tumor thereof |
| 09/22/2011 | WO2011100502A8 7-aminofuropyridine derivatives |
| 09/22/2011 | WO2011080510A8 Tricyclic compounds for use as kinase inhibitors |
| 09/22/2011 | WO2011066369A3 Antagonists of il-6 to raise albumin and/or lower crp |
| 09/22/2011 | WO2011063178A3 Intravenous infusion of curcumin and a calcium channel blocker |
| 09/22/2011 | WO2011059969A3 Mammalian metabolites of steroids |
| 09/22/2011 | WO2011059776A3 Prophylaxis of skin cancer with retinamides |
| 09/22/2011 | WO2011056477A3 Methods for treating inflammation and oxidative stress related diseases |
| 09/22/2011 | WO2011053750A3 Drug resistant immunotherapy for treatment of a cancer |
| 09/22/2011 | WO2011053618A3 Hydroxyl-terminated dendrimers |
| 09/22/2011 | WO2011050263A3 Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy |
| 09/22/2011 | WO2011050206A3 Compositions and methods for the treatment of sinonasal disorders |
| 09/22/2011 | WO2011050178A3 Targeted prdm gene or protein modulation therapeutic agents |
| 09/22/2011 | WO2011049979A3 Injectable formulations for intra- articular or peri-articular administration |
| 09/22/2011 | WO2011046596A3 Anti-cancer tamoxifen-melatonin hybrid ligand |
| 09/22/2011 | WO2011031833A3 Human anti-cancer antibodies |
| 09/22/2011 | WO2011009899A3 Phenalenones as antitumoral agents |
| 09/22/2011 | WO2010146370A3 Sox11 activating agents and uses thereof |
| 09/22/2011 | WO2010136168A8 Continuous administration of cilengitide in cancer treatments |
| 09/22/2011 | WO2010095042A8 Pyridocarbazole type compounds and applications thereof |
| 09/22/2011 | WO2009111653A3 Antiviral therapeutic agents |
| 09/22/2011 | US20110231942 Tiki1 and tiki2, wnt inhibitors |
| 09/22/2011 | US20110230637 Modified human thymic stromal lymphopoietin |
| 09/22/2011 | US20110230568 Heating of polymers and other materials using radiation for drug delivery and other applications |
| 09/22/2011 | US20110230564 Ant4 inhibitor compounds and methods of use thereof |
| 09/22/2011 | US20110230556 Diglycidic Ether Derivative Therapeutics and Methods for Their Use |
| 09/22/2011 | US20110230555 Enzyme Inhibitors and the Use Thereof |
| 09/22/2011 | US20110230550 Compounds, compositions and methods |
| 09/22/2011 | US20110230545 Eml4-alk fusion gene |
| 09/22/2011 | US20110230544 Modulation of c-reactive protein expression |
| 09/22/2011 | US20110230543 Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer |
| 09/22/2011 | US20110230540 Manassatin compounds and methods of making and using the same |
| 09/22/2011 | US20110230539 Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor |
| 09/22/2011 | US20110230531 Therapeutic compounds |
| 09/22/2011 | US20110230515 Compounds and methods for treatment and prevention of diseases |
| 09/22/2011 | US20110230509 Methods of use for cyclopamine analogs |
| 09/22/2011 | US20110230508 Novel Forms of a Fused Pyrrolocarbazole Compound |
| 09/22/2011 | US20110230506 Predictive marker for egfr inhibitor treatment |
| 09/22/2011 | US20110230500 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| 09/22/2011 | US20110230499 Hsp90 inhibitors for therapeutic treatment |
| 09/22/2011 | US20110230494 Heteroaryl compounds and uses thereof |
| 09/22/2011 | US20110230493 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors |
| 09/22/2011 | US20110230492 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 09/22/2011 | US20110230491 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 09/22/2011 | US20110230488 Hybrid-ionone and curcumin molecules as anticancer agents |
| 09/22/2011 | US20110230486 Modulators Of HEC1 Activity And Methods Therefor |
| 09/22/2011 | US20110230484 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| 09/22/2011 | US20110230482 Compounds modulating c-fms and/or c-kit activity |
| 09/22/2011 | US20110230481 Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent |
| 09/22/2011 | US20110230480 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| 09/22/2011 | US20110230476 Pi3 kinase inhibitors and uses thereof |
| 09/22/2011 | US20110230471 Benzonaphtyridine compounds as inhibitors of autotaxin |